<DOC>
	<DOCNO>NCT00001381</DOCNO>
	<brief_summary>Patients superficial transitional cell carcinoma bladder treat intravesical suramin phase I dose escalate study . The toxicity suramin administer fashion evaluate .</brief_summary>
	<brief_title>A Phase I Trial Using Suramin Treat Superficial Transitional Cell Carcinoma Bladder</brief_title>
	<detailed_description>Patients superficial transitional cell carcinoma bladder treat intravesical suramin phase I dose escalate study . The toxicity suramin administer fashion evaluate .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Suramin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm superficial transitional cell carcinoma bladder pathologically stag Tis , Ta , T1 . Visible tumor time treatment require . No metastatic disease muscle invasion . Clinically useful pretreatment bladder function require . No significant prostatic obstructive symptom associate impaired incomplete bladder empty . No active urinary tract infection . PRIOR/CONCURRENT THERAPY : At least 1 course prior standard intravesical therapy require . At least 4 week since intravesical treatment , resolution local systemic toxicity . PATIENT CHARACTERISTICS : Age : 18 . Performance status : ECOG 0 1 . Hematopoietic : WBC least 3,300 ; Hemoglobin least 10 g/dL . Hepatic : Bilirubin great 1.5 mg/dL ; AST ALT great 2 time normal . Renal : Creatinine great 1.5 mg/dL . OTHER : Medically able undergo cystoscopy . No pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Adult</keyword>
	<keyword>Intravesical Chemotherapy</keyword>
</DOC>